<code id='46D8874F10'></code><style id='46D8874F10'></style>
    • <acronym id='46D8874F10'></acronym>
      <center id='46D8874F10'><center id='46D8874F10'><tfoot id='46D8874F10'></tfoot></center><abbr id='46D8874F10'><dir id='46D8874F10'><tfoot id='46D8874F10'></tfoot><noframes id='46D8874F10'>

    • <optgroup id='46D8874F10'><strike id='46D8874F10'><sup id='46D8874F10'></sup></strike><code id='46D8874F10'></code></optgroup>
        1. <b id='46D8874F10'><label id='46D8874F10'><select id='46D8874F10'><dt id='46D8874F10'><span id='46D8874F10'></span></dt></select></label></b><u id='46D8874F10'></u>
          <i id='46D8874F10'><strike id='46D8874F10'><tt id='46D8874F10'><pre id='46D8874F10'></pre></tt></strike></i>

          Home / explore / hotspot

          hotspot


          hotspot

          author:explore    Page View:5257
          Adam's take main illustration
          Molly Ferguson/STAT

          Biotech is awash in PIPEs.

          The numbers behind these privately negotiated purchases of public-company stock are astounding. By my count, there have been 30 PIPE transactions involving public biotechs and institutional investors (mostly hedge funds) that have raised $4 billion in the first two months of the year.

          advertisement

          Just this week, five biotechs have brought in a combined $950 million via PIPEs, including Denali Therapeutics raising $500 million, the largest such financing this year. Crinetics Pharmaceuticals raised $350 million.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In